close

Matthew HG Katz, MD

Katz

University Of Texas, M.D. Anderson Cancer Center, Houston

Katz is an associate professor in the department of Surgical Oncology at the University of Texas M.D. Anderson Cancer Center. His clinical and research interests focus on patients with pancreatic cancer. He has extensive experience in the design and conduct of clinical trials and is currently the national principal investigator for an intergroup cooperative group study of the effects of preoperative therapy on patients with advanced pancreatic cancer.

He has published more than 90 articles that have described novel multi-modality treatment approaches for patients with this disease. He maintains a pancreatic surgery clinical practice.

 

RESEARCH FUNDED BY SKY FOUNDATION, INC.

December 2019 Update:

We completed accrual to the first national trial for patients with advanced pancreatic cancer anticipated to undergo surgery.  Sky Foundation helped to fund important aspects of this study including real-time central review of imaging studies as well as pathologic analysis of surgical specimens.

The study was designed to evaluate the role of preoperative chemotherapy and radiation therapy prior to surgery. Arm A included 8 cycles of FOLFIRINOX/surgery; Arm B included 7 cycles of FOLFIRINOX/SBRT/surgery.

At the interim analysis, Arm B was closed as the arm met pre-established futility endpoint. Arm A continued to accrue to final enrollment.

A total of 126 patients were randomized to the study.

We are awaiting maturation of the data.

 

PROJECT TITLE: PREOPERATIVE THERAPY NATIONAL CLINICAL TRIAL

PRINCIPLE INVESTIGATOR:

Matthew HG Katz, M.D., Chief, Pancreatic Surgery Service, Vice Chair for Research, Department of Surgical Oncology, The University of Texas MD Anderson Medical Cancer Center

PROJECT SUMMARY:

Alliance A021501 was a national clinical trial of preoperative therapy for patients with advanced pancreatic cancer

Patients with borderline resectable pancreatic cancer were randomly selected to receive either systemic chemotherapy or chemotherapy plus radiation therapy prior to anticipated surgical resection

Sky Foundation funds were utilized by clinicians to perform central radiologic and pathologic evaluation of each patient, enabling robust assessment of treatment response

The trial met its accrual goal earlier than anticipated, and the data are maturing

Results from this clinical trial will be presented in the next couple of years